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Bevacizumab exerts anti-angiogenic effects in cancer patients by inhibiting vascular
endothelial growth factor (VEGF). However, its use is still limited due to the development of
resistance to the treatment. Such resistance can be regulated by various factors, although
the underlying mechanisms remain incompletely understood. Here we show that bone
marrow-derived fibrocyte-like cells, defined as alpha-1 type I collagen-positive and
CXCR4-positive cells, contribute to the acquired resistance to bevacizumab. In mouse models
of malignant pleural mesothelioma and lung cancer, fibrocyte-like cells mediate the resistance
to bevacizumab as the main producer of fibroblast growth factor 2. In clinical specimens of
lung cancer, the number of fibrocyte-like cells is significantly increased in bevacizumab-
treated tumours, and correlates with the number of treatment cycles, as well as
CD31-positive vessels. Our results identify fibrocyte-like cells as a promising cell biomarker
and a potential therapeutic target to overcome resistance to anti-VEGF therapy.
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A
n adequate blood supply is essential for cancer cells to
survive and grow, thus, the concept of inhibiting tumour
angiogenesis has been applied to cancer therapy1,2.
Bevacizumab is a monoclonal antibody which blocks vascular
endothelial growth factor (VEGF) that is the most potent pro-
angiogenic factor to mediate multiple steps of tumour
angiogenesis3,4. The results from phase III clinical trials have
demonstrated that the addition of bevacizumab to conventional
chemotherapy improves the response rate and prolongs survival
of patients with non-small cell lung cancer (NSCLC) and colon
cancer5,6. However, in 2011, an announcement was made by the
US Food and Drug Administration revoking the approval of
bevacizumab for the treatment of metastatic breast cancer
because of its insufficient efficacy and safety7. The possible
reasons for the disappointing clinical results may include the lack
of biomarkers for the efficacy of or resistance to bevacizumab
treatment. A significant number of patients either do not
respond to anti-VEGF agents or develop resistance to them
after an initial response8,9. Therefore, it is crucial to investigate
the mechanism(s) of resistance and to identify biomarkers for
intrinsic and/or acquired resistance to bevacizumab treatment to
develop more effective cancer therapies.
For the mechanism of the resistance to anti-VEGF therapy, the
induction of hypoxia inducible factor (HIF) in tumour cells seems
to be the most intensively reported. The upregulated expression
of HIF in tumour cells under the hypoxic conditions initiated by
the inhibition of angiogenesis induces various pro-angiogenic
factors to regenerate microvessels in the tumour2,8,10,11. For host
cell-mediated resistance, the involvement of tumour-associated
macrophages (TAM), myeloid-derived suppressor cells (MDSC)
and vascular pericytes has been reported in mice12–16. Taken
together, the resistance to anti-VEGF therapy is regulated by
diverse mechanisms, including those related to the tumour
and host cells, although their respective functions remain
incompletely understood. Moreover, the current knowledge in
this field is mainly based on the observations in mouse models.
Verifying the major mechanism(s) of resistance in human
tumours is crucial.
In this study, we hypothesize that there are still uncovered
molecular and/or cellular mechanisms that regulate the resistance
to bevacizumab. To assess this hypothesis, we use mouse models
of malignant pleural mesothelioma (MPM) and lung cancer, and
lung cancer clinical specimens resected from patients after
bevacizumab therapy to explore the mechanism of resistance
to bevacizumab. We identify bone marrow-derived fibrocyte-like
cells, which are double-positive for alpha-1 type I collagen
and CXCR4, as a previously unrecognized cell type involved in
the acquired resistance to bevacizumab via their production
of fibroblast growth factor 2 (FGF2). Given that the soluble
factors have not been successfully developed as a practical
biomarker for the resistance to bevacizumab in clinic, fibrocyte-
like cells may be a promising cell biomarker and a potential
therapeutic target to overcome resistance to anti-VEGF therapy.
Results
Acquired resistance to bevacizumab in mouse models. Initially,
to investigate the mechanism by which tumours develop resistance
to VEGF inhibition, we orthotopically or intravenously injected
immunodeficient mice with human MPM cell lines (Y-MESO-14
and EHMES-10 cells) or human lung adenocarcinoma cell
lines (PC14PE6 and A549 cells) that highly express VEGF17–20.
Orthotopically injected Y-MESO-14 and EHMES-10 cells
produced thoracic tumours and pleural effusion, and the
intravenously injected PC14PE6 cells and A549 cells produced
multiple lung metastatic colonies. PC14PE6 cells also produced
pleural effusion. Seven days after tumour injection, continuous
treatment with bevacizumab was started. As expected,
bevacizumab treatment prolonged the survival of mice injected
with any of these four cell lines compared with the control group
(Fig. 1a) (Y-MESO-14; P¼ 0.0355, EHMES-10; P¼ 0.0046,
PC14PE6; P¼ 0.0002, A549; P¼ 0.0780, by a log-rank test).
In the models of Y-MESO-14 and PC14PE6 cells we confirmed
that bevacizumab effectively suppressed the tumour growth at
day 28 and 35 after tumour cell inoculation, respectively (Fig. 1b
and Table 1). Interestingly, the mice became moribund because
of tumour progression despite continuous bevacizumab
treatment (Fig. 1a,b), suggesting that the tumours exhibited
resistance to bevacizumab. To investigate whether this resistance
to bevacizumab was intrinsic or acquired, tumours were harvested
at different time points, and the microvessel density (MVD)
was immunohistochemically evaluated. MVD was significantly
reduced by bevacizumab treatment; however, it gradually increase
over time with continuous bevacizumab treatment (Fig. 1c,d
and Supplementary Fig. 1), suggesting that the resistance to
bevacizumab in these tumours was acquired. The subsequent
experiments were performed using MPM cell lines, or otherwise
indicated.
Induction of stromal FGF2 in bevacizumab-resistant tumours.
To identify the molecule(s) that contributes to the acquired
resistance to anti-VEGF therapy, we engineered human- or
mouse-specific primers to determine the differential changes in
the tumour (human) and/or stromal (mouse) gene expression by
performing a quantitative PCR (qPCR) analysis. The expression
of tumour cell-produced pro-angiogenic ligands was examined
using human-specific primers on day 28 after tumour cell
(Y-MESO-14) inoculation, and the upregulation of VEGFA and
FGF1 was observed. However, the expression of these molecules
was not changed or was under the limit of detection when the
protein expression was evaluated (Supplementary Fig. 2). On the
other hand, a qPCR analysis using mouse-specific primers
revealed that the expression of VEGFA, FGF2, FGFR2 and
platelet-derived growth factor receptor A (PDGFRA) was
upregulated in the bevacizumab-treated tumour stroma (Fig. 2a).
As both the ligand and receptor for stromal FGF signalling were
increased in the bevacizumab-treated tumours, we focused on
stromal FGF2 as a candidate molecule for the acquired resistance
to anti-VEGF therapy, and confirmed that the protein expression
of mouse FGF2 was significantly increased in the pleural effusion
of bevacizumab-treated Y-MESO-14 tumour-bearing mice
(Fig. 2b). The protein level of mouse VEGF-A was also increased
by 1.4-fold in the pleural effusion of bevacizumab-treated mice
compared with the control mice, although it did not reach to the
significance (Fig. 2c). Furthermore, an immunohistochemical
analysis demonstrated that the number of FGF2-positive cells to
significantly increase in bevacizumab-treated tumours compared
with the control-treated tumours on day 28 after tumour cell
inoculation (Fig. 2d,e).
FGFR inhibitor improves bevacizumab resistance. To verify the
role of FGF2 in bevacizumab resistance, tumour (Y-MESO-14
cells)-bearing mice were treated with a FGFR inhibitor
(BGJ-398)21 in combination with bevacizumab. The combination
therapy further prolonged the survival of mice compared with
the treatment with bevacizumab or BGJ-398 alone (Fig. 2f)
(control vs bevacizumab; P¼ 0.0042, control vs BGJ-398;
P¼ 0.0017, bevacizumab vs combination; P¼ 0.005, BGJ-398 vs
combination; P¼ 0.0078 by a log-rank test). In addition,
MVD was significantly reduced by the combination treatment
(Fig. 2g,h). The combination treatment of FGF2-neutralizing Ab
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and bevacizumab also reduced MVD in the tumour produced by
Y-MESO-14 cells compared with the bevacizumab treatment in
combination with control IgG (Fig. 2i,j). These results indicated
that stromal FGF2 plays a role in the resistance to anti-VEGF
therapy.
Fibrocyte-like cells as FGF2-expressing cells in the tumour. We
next examined what type of cells expressed FGF2 in the
bevacizumab-resistant tumour environment. To identify the
responsible cell type(s), we immunohistochemically assessed
various cell markers (Fig. 3a and Supplementary Fig. 3a). FGF2
expression did not co-localize with CD68, F4/80 or Gr-1,
suggesting that FGF2 was not expressed by macrophages or
MDSCs. However, many cells did co-express FGF2 and collagen
type I or CXCR4. Interestingly, collagen type I and CXCR4 were
predominantly co-localized, and the number of double-positive
cells was significantly increased in the bevacizumab-resistant
tumours (Fig. 3b,c and Supplementary Fig. 3b,c).
The unique phenotype with the co-expression of collagen type
I and CXCR4 was compatible to that of fibrocytes, which express
hematopoietic progenitor cell markers (CD45, CD34) and
produce extracellular matrix proteins, and also express chemo-
kines such as CXCR4 (ref. 22). An additional immunohisto-
chemical analysis showed that some collagen type I-positive cells
also expressed CD45 (Fig. 3d). Furthermore, these collagen
Table 1 | Effects of bevacizumab on thoracic tumours in mice.
Y-MESO-14 Thoracic tumour Pleural effusion
Incidence Weight (mg) Incidence Volume (ll)
Control (n¼4) 4/4 260 (210–330) 4/4 290 (200–700)
Bev 10mg (n¼ 5) 5/5 170 (100–250)* 4/5 50 (0–250)*
PC14PE6 Lung Pleural effusion
Weight (mg) Metastasis Incidence Volume (ll)
Incidence Number
Control (n¼ 7) 480 (320–880) 7/7 62 (25–87) 6/7 520 (0–750)
Bev 10mg (n¼ 7) 180 (170–200)w 6/7 17 (0–42)w 0/7 0
Bev 30 mg (n¼ 7) 180 (150–250)w 7/7 29 (4–101)* 0/7 0
MPM, malignant pleural mesothelioma; SCID, severe combined immunodeficient
Y-MESO-14 (human MPM) cells were orthotopically injected to SCID mice, and PC14PE6 (human lung adenocarcinoma) cells were intravenously injected to nude mice. These mice were treated with
bevacizumab (Bev) from day 7 after the tumour cell injection, and thoracic tumour, lung metastasis and pleural effusion were evaluated on day 28 (Y-MESO-14) or on day 35 (PC14PE6) after tumour cell
injection. Values are the median (minimum–maximum).
*Statistically significant difference compared with control group (Po0.05) by the Mann–Whitney-U-test.
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Figure 1 | Continuous treatment with bevacizumab induces acquired resistance in vivo. (a) The survival curve of tumour-bearing mice treated with
bevacizumab (bev) beginning from seven days after tumour cell injection. (left) Human MPM cell lines (Y-MESO-14 and EHMES-10) were injected
orthotopically. (right) Human lung cancer cell lines (PC14PE6 and A549) were injected via the tail vein. (b) The weights of Y-MESO-14 intrathoracic
tumours from the control and bevacizumab (bev)-treated groups at different time points. (c) Representative images of sections from Y-MESO-14
intrathoracic tumours stained for CD31. The tumours were harvested at different time points from the control and bevacizumab (bev)-treated groups. Scale
bar, 200 mm. (d) Quantitative evaluation of MVD (quantified as the total number of CD31þ structures/HPF) in each tumour of mice (n¼ 5 per group)
studied in c. The data are shown as the means±s.e.m *Po0.05 by a one-way ANOVA.
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type Iþ /CXCR4þ cells were confirmed to produce FGF2
(Fig. 3e), suggesting that the collagen type Iþ /CXCR4þ
fibrocyte-like cells play an essential role in the bevacizumab
resistance of tumours by expressing FGF2. There was still a
possibility that the collagen type Iþ cells were macrophages,
because macrophages may produce low levels of collagen, in
addition to CXCR4 (ref. 23). However, neither CD68 nor F4/80
co-localized with collagen type I (Fig. 3f).
To further confirm the characteristics of the collagen
type Iþ /CXCR4þ fibrocyte-like cells, we sought the origin of
these cells. Mice were given a bone marrow transplant (BMT)
from GFP transgenic mice before cancer cell inoculation, and the
collagen type I-positive cells in the tumour were assessed to
determine whether they were GFP-positive. Interestingly, the
number of GFP-positive cells was significantly increased in
the bevacizumab-resistant tumours (Fig. 4a,b), and the collagen
type Iþ /CXCR4þ cells were also GFP-positive (Fig. 4c),
suggesting that the origin of the collagen type Iþ /CXCR4þ cells
was the bone marrow. These results collectively indicated that
the collagen type Iþ /CXCR4þ cells in the tumour have
the distinctive features of fibrocytes. In addition, it was
also confirmed that FGF2 was predominantly produced by
GFP-positive cells in bevacizumab-resistant tumour in bone
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Figure 2 | Host-derived FGF2 is upregulated in the intrathoracic Y-MESO-14 tumours resistant to bevacizumab treatment. (a) A comparison of mouse
mRNA expression of pro-angiogenic factors in the intrathoracic Y-MESO-14 tumours treated with or without bevacizumab (bev). The fold-changes in
mRNA expression of the bevacizumab-treated tumours compared with control tumours are shown. *Po0.05 by the Mann–Whitney-U test. The changes in
the amounts of mouse (b) FGF2 (n¼ 8 per group) and (c) VEGF (n¼ 6 per group) in the pleural effusion of tumour (Y-MESO-14)-bearing mice treated with
or without bevacizumab (bev). *Po0.05 by the Mann–Whitney-U-test. (d) Representative images of FGF2-positive cells (green) in the sections from
Y-MESO-14 intrathoracic tumours treated with or without bevacizumab (bev). Scale bar, 100mm. (e) The number of FGF2-positive cells in the Y-MESO-14
tumours treated with bevacizumab (bev) compared with the control group (n¼ 9 per group). *Po0.01 by the Mann–Whitney-U-test. (f) The survival
curves of the tumour (Y-MESO-14)-bearing mice treated with bevacizumab (bev), BGJ-398 (an FGFR inhibitor), or both. Bevacizumab was continuously
given from day 7 after tumour cell injection. BGJ-398 was given from days 14–28. (g) Representative images of the CD31-positive vessels in the tumours
harvested from each group. Scale bar, 200mm. (h) Evaluation of microvessel density (MVD, quantified as the total number of CD31þ structures/HPF) in
the tumours from each group (n¼ 12 per group). *Po0.01 by a one-way ANOVA. (i) Representative images of the CD31-positive vessels in the tumours
harvested from mice treated with bevacizumab (bev) in combination with FGF2 Ab or control IgG. Scale bar, 200mm. (j) Evaluation of MVD in each group
(n¼ 12 per group). *Po0.01 by the Mann–Whitney-U-test. All data are shown as the means±s.e.m.
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We finally performed the flow cytometric analysis to confirm
that the number of fibrocyte-like cells was increased in the
bevacizumab-resistant tumour. Single-cell suspension of control-
or bevacizumab-treated tumour was stained with CD45, collagen
type I and CXCR4 to detect fibrocyte-like cells. The percentage of
CD45þ /collagen type Iþ /CXCR4þ cells was significantly
increased in the bevacizumab-resistant tumour (Fig. 5a,b). The
average number of leukocytes (CD45þ cells) in control- and
FGF2




































































Figure 3 | The identification of collagen type Iþ/CXCR4þ cells as FGF2-producing cells in the intrathoracic tumours produced by Y-MESO-14 cells.
(a) Representative images of tumour sections from mice treated with bevacizumab. FGF2 (green) was co-stained along with CD68, F4/80, Gr-1, collagen
type I or CXCR4 (red). Scale bar, 100 mm. (b) Double staining of collagen type I and CXCR4 in tumours from mice treated with or without bevacizumab
(bev). Scale bar, 200mm. (c) The number of double-positive cells in the tumours was compared between the control- and bevacizumab (bev)-treated
groups (n¼ 20 per group). The data are shown as the means±s.e.m. *Po0.01 by the Mann–Whitney-U-test. (d) Representative images of double staining
for collagen type I and CD45 in Y-MESO-14 tumours treated with bevacizumab. Scale bar, 100mm. (e) Representative images of triple staining for collagen
type I, CXCR4 and FGF2 in the tumours treated with bevacizumab. Scale bar, 50mm. (f) Representative images of double staining for collagen type I (green)
and CD68 or F4/80 (red) in Y-MESO-14 tumours treated with bevacizumab. Scale bar, 100mm.
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bevacizumab-treated tumour was 1.56 104 and 2.19 104 cells
per 1mg of tumour tissue, respectively (not significant with
Student’s t-test), whereas the number of fibrocyte-like cells was
1.12 103 and 3.80 103 per 1mg of tumour tissue, respectively
(Po0.05 with Student’s t-test). On the other hand, the percentage
of CD45þ /Gr-1þ MDSCs was not changed by bevacizumab
treatment (Fig. 5c), whereas the percentage of CD45þ /F4/80þ
macrophages was slightly increased with bevacizumab treatment
(Fig. 5c).
Since the limitation of this preclinical study is that we used
immunodeficient mice that lack lymphocytes, we also employed
syngeneic mouse model using B16 melanoma cells and C57BL/6
mice to verify the role of other immune cells in the acquired
resistance to anti-VEGF therapy (Supplementary Fig. 4). We
subcutaneously injected B16 cells to C57BL/6 mice, and treated
these mice with SU5416, a VEGF receptor inhibitor, continuously
from day 5 after tumour cell inoculation. Similar to the results
obtained from immunodeficient mice experiment, the tumour
grew and MVD was increased regardless of SU5416 treatment after
the initial response (Supplementary Fig. 4a–c). These tumour
regrowth were suppressed by combination treatment with SU5416
and BGJ-398 (Supplementary Fig. 4d). In this model, the
fibrocyte-like cells were detected as CD45þ /FSP-1þ cells, and
the increased number of tumour-infiltrated CD45þ /FSP-1þ cells
after SU5416 treatment were confirmed by immunofluorescence
(Supplementary Fig. 4e,f). The effect of SU5416 treatment on the
infiltration of lymphocytes into the tumour was also examined by
immunofluorescence. The numbers of tumour-infiltrated CD3- or
CD19-positive cells were significantly low compared with that of
fibrocyte-like cells, and did not change by SU5416 treatment
(Supplementary Fig. 4g).
Character of fibrocyte-like cells in the resistant tumour. To
confirm the results from immuonofluorescence and flow
cytometry indicating that the number of fibrocyte-like cells was
increased and that these were the FGF2-producing cells in the
bevacizumab-resistant tumours, we isolated and characterized the
fibrocyte-like cells from mouse tumour tissue. Before this, fibro-
cyte-like cells and fibroblasts were differently isolated from mouse
normal lungs, and their gene expression profiles were compared.
As reported previously, fibrocyte-like cells expressed higher levels
of CXCR4 and CD45, and relatively lower levels of COL1A1
compared with fibroblasts (Fig. 6a)22. FGF2 expression in
fibrocyte-like cells was lower than that in fibroblasts. When
fibrocyte-like cells were isolated from the mouse tumour tissues,
the number of these cells was significantly increased in the
bevacizumab-resistant tumours compared with the control-
treated tumours (Fig. 6b). On the other hand, the expression of
FGF2, as well as CXCR4, CD45 and COL1A1, in the isolated
fibrocyte-like cells was similar between the tumours (Fig. 6c),
suggesting that the increase of FGF2 in bevacizumab-treated
tumours was due to the increase in the number of these cells.
Mechanism in the recruitment of fibrocyte-like cells. To
investigate the mechanism(s) underlying the functions and
recruitment of fibrocyte-like cells in the bevacizumab-resistant
tumours, in vitro cell-proliferation experiments were performed
using human fibrocyte-like cells derived from peripheral blood
mononuclear cells. We first confirmed that bevacizumab or
BGJ-398 inhibited VEGF- or FGF2-induced proliferation of
human umbilical vein endothelial cells (HUVECs), respectively
(Supplementary Fig. 5). As reported previously, the supernatant of
fibrocyte-like cells induced the proliferation of the HUVECs24, but
interestingly, their proliferation was inhibited only by BGJ-398, not
by bevacizumab (Supplementary Fig. 5), supporting our results
showing that the fibrocyte-like cells express FGF2.
To determine the mechanism by which fibrocyte-like cells were
recruited into the tumour environment, we performed human-
specific gene profiling using tumour tissues (Y-MESO-14).





























Figure 4 | The recruitment of bone marrow-derived cells in bevacizumab-resistant tumour. Mice were given a bone marrow transplant (BMT) from GFP
transgenic mice before cancer cell inoculation. (a) Representative images of GFP-positive bone marrow cells (green) recruited into the control or
bevacizumab (bev)-treated tumours. Scale bar, 200mm. (b) The percentages of GFP-positive areas in the tumours were compared between the control-
and bevacizumab (bev)-treated groups (n¼ 8 per group). The data are shown as the means±s.e.m. *Po0.01 by the Mann–Whitney-U-test. (c)
Representative images of triple staining for GFP, collagen type I and CXCR4 in the tumours treated with bevacizumab. Scale bar, 50 mm. (d) Representative
images of double staining for GFP and FGF2 in the tumours treated with bevacizumab. Scale bar, 100 mm.
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bevacizumab-resistant tumours compared with the control
tumours, we focused on CXCL12, the ligand of CXCR4
(Supplementary Fig. 6). Because CXCL12 is the target molecule
of HIF-1a, the hypoxic condition resulting from bevacizumab
treatment could lead the tumour cells to produce CXCL12, which
would in turn prompt the CXCR4þ cells to migrate into the
tumour. Indeed, the area of hypoxia was significantly increased
(Fig. 7a) and the CXCL12 expression was confirmed to be
significantly upregulated in the bevacizumab-treated Y-MESO-14
tumours compared with the control tumours (Fig. 7b, left panel).
CXCL12 expression was also induced in a chemical hypoxic
condition induced by treating Y-MESO-14 cells with deferox-
amine (DFX) in vitro (Fig. 7b, right panel).
We then examined whether the CXCL12 induced by the
hypoxic condition might be able to regulate the migration of
fibrocyte-like cells. As expected, the number of migrated
fibrocyte-like cells was strongly increased when the cells were
treated with the supernatant of Y-MESO-14 cells cultured under
hypoxic conditions. Moreover, this induction of migration was
inhibited by a CXCR4 inhibitor (AMD3100)25, indicating the
important role of the CXCL12-CXCR4 axis in the migration of
fibrocyte-like cells (Fig. 7c,d).
To further verify the importance of the fibrocyte-like cells
recruited by the CXCL12-CXCR4 axis in the development of
bevacizumab resistance in vivo, tumour (Y-MESO-14)-bearing
mice were treated with bevacizumab and/or AMD3100. The
combination of AMD3100 with bevacizumab further inhibited
tumour growth (Fig. 7e), angiogenesis (Fig. 7f) and fibrocyte-like
cells recruitment (Fig. 7g), suggesting that CXCR4 inhibition
could partially overcome the development of bevacizumab
resistance by inhibiting the re-angiogenesis mediated by
fibrocyte-like cells. On the other hand, AMD3100 is known to
induce the mobilization of hematopoietic stem cells (HSCs) from
























































































































































Figure 5 | The isolation of mouse fibrocyte-like cells from Y-MESO-14 tumours by flow cytometry. (a) Representative analysis of the detection of
fibrocyte-like cells. The tumour tissues were harvested and single-cell suspended from control- or bevacizumab (bev)-treated mice on day 28. Fibrocyte-
like cells were detected as CD45þ/collagen type Iþ/CXCR4þ population. Each samples contained tumour tissues from two mice. (b) The comparison of
the percentage of CD45þ/collagen type Iþ/CXCR4þ cells between control- and bevacizumab (bev)-treated group (n¼ 3 in each group, each samples
contained tumour tissues from two mice). *Po0.05 by Student’s t-test. The data are shown as the means±s.e.m. (c) MDSCs or Macrophages were
detected as CD45þ/Gr-1þ cells or CD45þ/F4/80þ cells, respectively. Each samples contained tumour tissues from two mice. Data are the
representative of two experiments with similar results.
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bone marrow transplantation in non-solid tumours26,27. Thus,
since we observed that the number of fibrocyte-like cells in the
tumour was inhibited by AMD3100 treatment, there is a
possibility that its inhibition might be due to the reduction in
the production of fibrocyte-like cells from their BM-ancestor
cells. To test this hypothesis, we analysed Sca-1þ HSCs in the
BM of bevacizumab- or bevacizumab plus AMD3100-treated
mice by flow cytometry. As a result, the addition of AMD3100 in
bevacizumab treatment did not affect the number of HSCs in BM
(Supplementary Fig. 7) suggesting that the reduced number of
fibrocyte-like cells in the tumours treated with AMD3100 was not
due to the effects on BM in this model.
Ceradini et al.28 have demonstrated that HIF-1-induced
CXCL12 expression increases the adhesion, migration and
homing of circulating CXCR4þ endothelial progenitor cells to
ischaemic tissue using a mouse ischaemic model. Because VEGF
inhibition produces low oxygen conditions in the tumour, these
results supports our data showing that bevacizumab treatment
recruits fibrocyte-like cells via the CXCL12-CXCR4 axis, although
other mechanisms are supposed to be involved29,30. Other than
CXCR4-positive population, fibrocytes are reported to have a
minor population positive of CCR7 instead of CXCR4 (ref. 30). We
performed mouse-specific qPCR analysis using the tumour tissues
produced by Y-MESO-14 cells, and found that the expressions of
both stromal CXCR4 and CCR7 were increased by bevacizumab
treatment, and the expression of CCR7 was significantly lower in
the tumour tissue compared with CXCR4 expression,
(Supplementary Fig. 8), suggesting that CXCR4-positive
population plays a role in bevacizumab resistance. In addition, it
is also possible that fibrocyte-like cells proliferate in the tumour
tissue instead of recruiting from the blood stream. To confirm
whether bone marrow-derived cells (BMDCs) proliferate in the
tumour tissue, GFP-positive cells were co-stained with mouse-
specific Ki67 using the tumour sample from BMT experiment. As a
result, only 9.6% of GFP-positive cells were Ki67-positive,
suggesting that the majority of fibrocyte-like cells in the tumour
are recruited from the blood (Supplementary Fig. 9).
Pericytes are another important cell type to cover and protect
endothelial cells from death induced by VEGF inhibition15,31,32.
The change in pericyte coverage was also investigated
immunohistochemically in our model, but we found that the
pericyte coverage was not significantly increased in the
bevacizumab-resistant tumours compared with the control
tumours (Supplementary Fig. 10).
Fibrocyte-like cell recruitment in human lung cancer tissue.
We finally investigated human clinical samples to assess whether
there was tumour infiltration of fibrocyte-like cells in human lung
cancer. Fibrocyte-like cells (CD45þ /FSP-1þ ) were immunohis-
tochemically detected in surgically resected tumours from lung
adenocarcinoma patients. Interestingly, the number of CD45þ /
FSP-1þ cells was significantly higher in the tumour from patients
who received bevacizumab-containing chemotherapy before the
surgery compared with the tumour from the patients who received
chemotherapy alone or who received no prior therapy (Fig. 8a–c).
In addition, the number of FGF2-expressing cells was also sig-
nificantly increased in the tumours from patients who received
bevacizumab-containing chemotherapy (Fig. 8d–f). Most of the
FSP-1-positive cells were also FGF2-positive, whereas the CD68-
positive cells were FGF2-negative (Fig. 8g,h). Furthermore, we co-
immunostained FSP-1 and CD3, CD19 or CD68 to verify the
possibility that FSP-1-positive cells were lymphocytes or macro-
phages, and found that these markers did not co-localize with
FSP-1 (Supplementary Fig. 11a). CD3-positive cells were detected
to a certain extent in human lung cancer tissue although the
number of these cells did not change with bevacizumab treatment
(Supplementary Fig. 11b). CD19- or CD68-positive cells were
minor populations regardless of bevacizumab treatment. Recently,































































































Figure 6 | The isolation and characterization of mouse fibrocyte-like cells from normal mouse lungs or Y-MESO-14 tumours. (a) Fibroblasts (Fb) and
fibrocyte-like cells (Fc) were isolated from the normal mouse lungs, and their mRNA expression levels were compared (n¼ 3 per group). *Po0.01 by
Student’s t-test. (b,c) Fibrocyte-like cells were isolated from control- or bevacizumab (bev)-resistant tumours. (b) A comparison of the number of isolated
fibrocyte-like cells (n¼ 6 per group). (c) A comparison of the mRNA expression in isolated fibrocyte-like cells (n¼6 per group). **Po0.05 by the Mann–
Whitney-U-test. All data are shown as the means±s.e.m.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9792
8 NATURE COMMUNICATIONS | 6:8792 | DOI: 10.1038/ncomms9792 | www.nature.com/naturecommunications
promotes tumour resistance to VEGF inhibition by mediating
immature myeloid-cell mobilization and recruitment into the
tumour microenvironment in mice. The involvement of IL-17
producing cells was also investigated in our clinical samples;
however, the number of IL-17-producing cells was not increased in
the bevacizumab treatment group in our study (Supplementary
Fig. 12). Of note, the number of CD45þ /FSP-1þ cells in the
bevacizumab-treated patients was significantly correlated with the
number of treatment cycles of bevacizumab (Fig. 8i) and with the
vessel length in the tumour (Fig. 8j). Together with the results from
mouse models, these findings indicate that fibrocyte-like cells may
be key regulatory cells in the tumour microenvironment that are
involved in the acquisition of resistance to anti-VEGF therapy
through their production of FGF2.
Discussion
Fibrocytes, which are present in the peripheral circulation as
a minor population of leukocytes, were first identified more
than a decade ago34. Subsequent studies revealed that they are
monocyte-derived cells that have features of both macrophages
and fibroblasts22–24,35,36. Since there is no single specific marker
for fibrocytes at present, the combination of intracellular collagen
staining and the expression of a hematopoietic marker, such as
CD45, plus either CD34 or CXCR4, has been considered to be a
sufficiently accurate criterion for identifying fibrocytes22,23,37. In
some studies, fibrocytes are considered as the cells double positive
of CD45 and FSP-1 (refs 38–40). Based on their fibrogenic
properties, fibrocytes were previously reported to be involved in






















































































































































































Figure 7 | The involvement of CXCL12-CXCR4 axis in the fibrocyte-like cell-mediated angiogenesis. (a) Assessment of hypoxic lesion in the tumour with
immunohistochemistry using anti-CA9 antibody. (left) representative images of the hypoxic lesion stained in brown in the tumour produced by Y-MESO-14
cells treated with or without bevacizumab (bev). Tumours were harvested 28 days after the tumour cell-injection. Scale bar, 200mm. (right) Evaluation
of CA9-positive area (n¼ 6 per group). *Po0.05 by the Mann–Whitney-U-test. (b) (left) the relative mRNA expression of human (tumour cell)
CXCL12 in control- or bevacizumab (bev)-treated Y-MESO-14 tumour tissues (n¼ 5 per group). *Po0.01 by the Mann–Whitney-U-test. Right, the mRNA
expression of CXCL12 in Y-MESO-14 cells cultured under normoxia or chemical hypoxia induced by deferoxamine (DFX) in vitro (n¼ 3 per group).
*Po0.01 by Student’s t-test. (c) Representative images of the migrated fibrocyte-like cells in vitro. Fibrocyte-like cells were cultured with or without a
CXCR4 inhibitor (AMD3100) in the upper chamber, and those that migrated towards the lower chamber were stained. The lower chamber contained
Y-MESO-14 cells cultured under normoxia or chemical hypoxia. Scale bar, 200mm. (d) The number of fibrocyte-like cells that migrated under each
condition. *Po0.05 by a one-way ANOVA. All in vitro data are representative of duplicate experiments with similar results. (e–g) The effect of CXCR4
inhibition in addition to bevacizumab treatment in vivo. Thoracic tumours (Y-MESO-14) were harvested from mice treated with bevacizumab (bev) or
bevacizumab in combination with AMD3100 (AMD). (e) A comparison of the tumour weights. (f) A comparison of MVD. (f) A comparison of the number
of fibrocyte-like cells (collagen type 1þ/CXCR4þ cells) (n¼ 6–7 per group). *Po0.01 by the Mann–Whitney-U-test. All in vivo and in vitro data are shown
as the means±s.e.m.
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fibrosis, bronchial asthma and cardiovascular disease41–45. In the
field of cancer, however, only a small number of studies have
reported the existence of fibrocytes in the peripheral blood of
patients46, and the role of fibrocytes in the pathogenesis of cancer
has been unknown, and to the best of our knowledge, their role in
drug resistance has not yet been examined.
Although it is complicated to determine the precise identity of
monocyte-derived cell populations because of their plasticity and
phenotypical overlaps, we applied the term ‘fibrocyte-like cells’
for collagen type Iþ /CXCR4þ (and also CD45þ in some
experiments) cells or CD45þ /FSP-1þ cells, and showed those
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Figure 8 | The recruitment of fibrocyte-like cells in the surgically resected human lung cancer specimens. (a) Representative images of fibrocyte-like
cells that were double-positive for CD45 (red) and FSP-1 (brown), in the tumour tissues of patients treated with neoadjuvant chemotherapy containing
bevacizumab (bev), chemotherapy without bev or with no prior therapy. Scale bar, 100 mm. (b) The number of CD45þ/FSP-1þ cells in the individual
tumour samples. (c) The average number of CD45þ/FSP-1þ cells in each group. *Po0.01 by a one-way ANOVA. (d) Representative images of the FGF2-
positive cells (brown) in each group. Scale bar, 100 mm. (e) The number of FGF2-positive cells in the individual tumour samples. (f) The average number of
FGF2-positive cells in each group. *Po0.01 by a one-way ANOVA. (g,h) Representative images of the double staining for (g) FSP-1 (red) or (h) CD68 (red)
and FGF2 (brown) in the tumour from patient no. 1. (g) The arrows indicate double-positive cells. (h) The arrow indicates a CD68 single-positive cell, and
the arrowhead indicates a FGF2 single-positive cell. Scale bars, 100 mm (top), 50mm (bottom). (i,j) The correlation of the number of CD45þ/FSP-1þ cells
in the tumour and (i) the cycles of bevacizumab used and (j) the vessel length in the tumour. Each dot represents an individual tumour sample from patient
nos 1–10. The correlation was estimated by Spearman’s correlation and a linear regression analysis (the best-fit line is indicated together with the 95%
confidence bands). The red dot indicates patient no. 1, who underwent surgical resection after developing obvious clinical resistance to bevacizumab.
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bevacizumab treatment in both mouse models and human
clinical tissue samples. To our knowledge, the previous studies
using clinical specimens to investigate the mechanism of the
resistance to anti-angiogenic therapy have been focused on the
soluble factors present in peripheral blood such as VEGF,
placental growth factor, CXCL12 and FGF2 (refs 47–52).
Considering that these soluble factors have not been
successfully developed as a practical biomarker in clinic, and
because the cell–cell interactions play crucial roles in the tumour
microenvironment, it seems logical to investigate tissue samples.
In our study, not all of the patients who received bevacizumab
clinically acquired resistance before the surgery. However, patient
no. 1, who had the highest number of fibrocytes and the highest
FGF2 expression in the tumour tissue (Fig. 8b,e), underwent
surgical resection after developing obvious clinical resistance to
bevacizumab. This might support the involvement of fibrocyte-
like cells in the resistance of human lung cancer to anti-VEGF
therapy. In addition, the clinical data also suggest that the
mechanism of resistance mediated by fibrocyte-like cells has
already been ‘switched on’ before the development of clinically
relevant tumour recurrence. Although it is challenging to obtain
surgically removed samples after bevacizumab treatment, given
the small number of such samples available, continuous efforts
are warranted to clarify the cellular mechanism by which
fibrocyte-like cells may mediate the acquired resistance to anti-
angiogenic therapy.
Various modes of resistance to anti-angiogenic therapy are
reviewed in detail by Bergers and Hanahan10. According to the
current knowledge, the major mechanisms of host-mediated
acquired resistance include revascularization subsequent to the
upregulation of alternative pro-angiogenic signals; the
recruitment of pro-angiogenic cells from the bone marrow and
the protection of the vasculature by pericyte coverage. Among the
soluble factors that could mediate the angiogenic switch, FGF2
appears to be one of the most intensively reported factor in both
the experimental and clinical settings47,48,53–55. With regard to
the cells responsible for producing FGF2 in the resistant tumours,
the results from our study demonstrated that fibrocyte-like cells
may be a major source, in addition to macrophages and the
tumour cells themselves.
Tumour angiogenesis, and possibly the re-angiogenesis that
develops in the tumours resistant to anti-angiogenesis therapy, can
be regulated not only by soluble pro-angiogenic factors but also by
the recruitment of various BMDCs that have the capacity to
regenerate the blood vessels. Those BMDCs include TAMs, TIE2þ
monocytes, VEGFR1þ hemangiocytes and CD11bþ myeloid
cells56–61. In this study, we demonstrated that the fibrocyte-like
cells, but not CD3- or CD19-positive cells, in the tumour
microenvironment are involved in the acquisition of resistance to
anti-VEGF therapy. As previously reported12,13, TAMs do
contribute on tumour angiogenesis. There is a possibility that, in
addition to fibrocyte-like cells, tumour-infiltrated macrophages
may also contribute on angiogenesis in our model, as the number
of CD45þ /F4/80þ macrophages was slightly increased with
bevacizumab treatment (Fig. 5c). For this, future efforts are
warranted to clarify the role of macrophages in the resistance to
anti-VEGF therapy in this model. Since we observed in human
clinical specimens and in immunodeficient mouse model that F4/
80þ or CD68þ cells did not express FGF2 (Figs 3a and 8h),
macrophages may contribute on the acquired resistance via the
mechanism(s) other than FGF2-FGFR signalling.
Among the cells that could be able to contribute on the
resistance to anti-angiogenesis therapy, CD11bþGr1þ MDSCs
were reported to be directly involved in the tumour refractoriness
to anti-VEGF therapy in a mouse model14. In this study, the
number of tumour-infiltrated Gr-1þ cells was not changed after
anti-VEGF therapy. However, contribution of MDSCs on acquired
resistance to anti-VEGF treatment should not be ignored, as recent
reports suggest that some populations of MDSCs (CCR2þ or
CD11chigh/ CD14 / CD123 ) have a potential to differentiate to
fibrocytes and encourage tumour progression46,62. Since these cells
have not yet been clearly identified in humans, future technological
developments are needed to determine whether these cells exist
and are a cause of resistance in humans. There are several potential
clinical implications of the present study. First, based on our
preclinical data generated using mouse models, dual inhibition of
FGF2 and VEGF could provide a more durable response to anti-
angiogenesis therapy compared with single treatment with
bevacizumab. Moreover, it is of interest to ask what other
molecules (or cells) are involved after the resistance against
FGF2 and VEGF. Second, fibrocyte-like cells could be the key
regulator of the resistance to bevacizumab therapy. Thus, it may be
instructive to target these cells to more effectively inhibit tumour
angiogenesis. Third, fibrocyte-like cells could also be useful as a
cellular biomarker for the resistance to bevacizumab therapy. As
such, it would be interesting to develop the technology to detect
these cells in the peripheral blood to predict the resistance to anti-
angiogenesis therapy.
In summary, we uncovered that a cell type appears to mediate
the resistance to anti-VEGF therapy. It is crucial to focus not only
on the soluble factors but also on the responsible cells, to
understand the mechanisms of resistance to treatment, and
comprehending the mechanism mediated by fibrocyte-like cells
might help to develop more effective and durable anti-angiogen-
esis therapy.
Methods
Cell lines. The human MPM cell lines, Y-MESO-14 and EHMES-10, were kindly
provided by Dr Y. Sekido (Aichi Cancer Center Research Institute, Nagoya, Japan)
and Dr H. Hamada (Hiroshima University Graduate School of Health Science,
Hiroshima, Japan), respectively. The human NSCLC cell line PC14PE6, and mouse
melanoma cell line B16 were kindly provided by Dr I.J. Fidler (M.D. Anderson
Cancer Center, TX). The human NSCLC cell line, A549, was purchased from the
American Type Culture Collection. Normal HUVECs were purchased from
KURABO (Osaka, Japan). These cell lines were authenticated at BEX CO., LTD
(Tokyo, Japan) using a Multiplex STR assay. Human thoracic tumour cell lines
were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated
fetal bovine serum (FBS), penicillin (100Uml 1) and streptomycin (50 mgml 1).
B16 cells were maintained in DMEM medium supplemented with 10% heat-
inactivated FBS, penicillin (100Uml 1) and streptomycin (50 mgml 1). HUVECs
were maintained in EBM-2 (Lonza, Basel, Switzerland). All cells were cultured at
37 C in a humidified atmosphere of 5% CO2 in air.
Reagents. Bevacizumab, an immunoglobulin (Ig) G1 monoclonal antibody
targeting VEGF-A, was obtained from Chugai Pharmaceutical (Tokyo, Japan). For
in vivo studies, bevacizumab was diluted in phosphate-buffered saline (PBS).
BGJ-398, a FGFR-specific inhibitor, was purchased from Chemietek (Indianapolis,
IN). For the in vitro studies, 4mM stock solutions were prepared in DMSO. For the
in vivo studies, BGJ-398 was formulated in PEG300/D5W (2:1). FGF2-neutralizing
antibody was purchased from R&D systems (Minneapolis, MN). AMD3100, a
selective CXCR4 antagonist, was purchased from Sigma (St Louis, MO). For
in vitro studies, 10mgml 1 stock solutions were prepared in PBS. SU5416, a
VEGFR-specific inhibitor, was purchased from Abcam (Cambridge, MA). For the
in vivo studies, SU5416 was formulated in DMSO. An anti-mouse IL-2 receptor
b-chain monoclonal antibody, TM-b1, was supplied by Drs M. Miyasaka and
T. Tanaka (Osaka University, Osaka, Japan).
Animals. Six-weeks-old male athymic BALB/c nude mice, severe combined
immunodeficient (SCID) mice and C57BL/6 mice were obtained from Charles
River Japan Inc. (Shiga, Japan) or CLEA Japan (Tokyo, Japan), respectively. Six-
weeks-old male C57BL/6-BALB/c-nu/nu-EGFP mice were obtained from SLC
Japan Inc. (Shizuoka, Japan). Mice were maintained under specific pathogen-free
conditions throughout this study. All experiments were performed in accordance
with the guidelines established by the Tokushima University Committee on Animal
Care and Use. At the end of each in vivo experiment, the mice were anaesthetized
with isoflurane and euthanized humanely by cutting the subclavian artery. All
experimental protocols were reviewed and approved by the animal research
committee of The University of Tokushima, Japan.
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In vivo orthotopic implantation models of human MPM cells. For orthotopic
implantation, SCID mice were anaesthetised with tribromoethanol and had their
right chest wall shaved. After sterilization of the chest wall with 70% ethanol, their
right chest skin was cut, and their parietal pleura were exposed. They were then
injected with Y-MESO-14 or EHMES-10 cells (1.0 106 cells per mouse) suspended
in 0.1ml PBS into the thoracic cavity through the parietal pleura using a 27G
needle63. To determine the therapeutic efficacy of bevacizumab against intrathoracic
implanted tumour tissue, the mice were treated twice a week with 10mg per mouse
bevacizumab by intraperitoneal injection, beginning 1 week after tumour cell
inoculation. The mice were killed humanely under anaesthesia, and the thoracic
tumours were removed and weighed 21, 28, 35, 42 days (Y-MESO-14) or 28 and 65
days (EHMES-10) after tumour cell inoculation. Whole tumour tissues were
weighted, and the weights were compared between bevacizumab-treated group and
vehicle-treated group. The pleural effusion was harvested using a 1ml syringe. To
determine the effects of bevacizumab on survival, mice were treated twice a week
with 10mg per mouse bevacizumab or vehicle control from day 7 until they became
moribund. To examine the effects of combination treatment with bevacizumab and
BGJ-398, the mice were treated once daily with 200mg per mouse BGJ-398 or vehicle
control by oral gavage from days 21 to 35. To determine the effects of combination
treatment with bevacizumab and FGF2-neutralizing antibody, the mice were treated
with 20mg per mouse goat anti-FGF2 antibody or control goat IgG (R&D systems,
Minneapolis, MN) by subcutaneous injection on days 7 and 14 in combination with
continuous bevacizumab treatment stated above. To examine the effects of
combination treatment with bevacizumab and a CXCR4 antagonist (AMD3100), the
mice were treated once daily with 5mg kg 1 per mouse AMD3100 or vehicle
control by subcutaneous injection from days 7 to 42. Considering the inhibitory
effect of AMD3100 in the anti-tumour immune response via NK cells, all mice were
pretreated with TM-b1 (1mg per 0.3ml PBS per mouse) by intraperitoneal injection
to deplete NK cells two days before tumour inoculation64. The mice were killed
humanely under anaesthesia, and thoracic tumours were removed on day 42. Whole
tumour tissues were weighted, and the weights were compared between the groups
treated with combination therapy and bevacizumab monotherapy.
In vivo lung metastasis model. To establish the lung metastasis model, nude mice
were intravenously inoculated via the tail vein with PC14PE6 or A549 tumour cells
(1.0 106 cells per mouse) suspended in 0.2ml of PBS65. Mice were treated with
bevacizumab with the same procedure used in the orthotopic models.
GFP bone marrow chimeric mouse model. Bone marrow cells from C57BL/6-
BALB/c-nu/nu-EGFP mice were extracted from the tibias and femurs and trans-
planted by tail-vein injection (5.0 106 cells per mouse) into irradiated (two doses
of 3.5 Gy, 3 h apart) nude mice. Three weeks after the BMT, the mononuclear cells
in the peripheral blood of recipient mice were screened by Keyence BZ-9000
microscopy (Keyence, Tokyo, Japan), and were confirmed to be over 90% GFP-
positive. The mice were pretreated with TM-b1 (1mg per 0.3ml PBS per mouse)
by intraperitoneal injection to deplete NK cells three weeks after the BM transplant.
Two days later, the mice were orthotopically inoculated with Y-MESO-14 tumour
cells (1.0 106 cells per mouse) and treated twice a week with 10 mg per mouse
bevacizumab or vehicle control by intraperitoneal injection from day 7. The mice
were killed humanely under anaesthesia and thoracic tumours were removed 28
days after tumour cell inoculation.
In vivo subcutaneous implantation model of B16 cells. Mouse melanoma cell
line, B16 cells (1.0 106 cells per mouse) suspended in 0.1ml PBS were sub-
cutaneously inoculated to the right flank of C57BL/6 mice. Tumour size was
measured by vernier caliper at least three times a week. Volume¼ ab2 2 1 (a, long
diameter; b, short diameter). To determine the effect of SU5416 on tumour growth,
the mice were treated once a day with SU5416 (5 or 10mg per kg per mouse) or
DMSO by intraperitoneal injection from day 5 until they became moribund. When
the average of tumour size reached 5000–6000mm3, the mice were killed humanely
and the tumours were resected for the further analyses. To examine the effects of
combination treatment with SU5416 and BGJ-398, the mice were treated once daily
with 200 mg per mouse BGJ-398 or vehicle control by oral gavage from day 5, in
addition to SU5416 treatment.
Immunofluorescence of mouse tumour tissues. The excised tumour tissues
from the model mice were placed into OCT compound (Sakura Finetechnical Co.,
Tokyo, Japan) and snap-frozen. Frozen tissue sections (8 mm thick) were fixed with
4% paraformaldehyde solution in PBS and used for the identification of fibrocyte-
like cells using a goat anti-COL1A1 polyclonal antibody (1:100 dilution, Santa
Cruz, Dallas, TX), rabbit anti-FSP-1 polyclonal antibody (1:100 dilution, Neo-
markers/Lab Vision Corporation, Fremont, CA), rat anti-CXCR4 monoclonal
antibody (1:100 dilution, 247506, R&D systems, Minneapolis, MN) and rat anti-
CD45 monoclonal antibody (1:50 dilution, 30-F11, BD Pharmingen, Franklin
Lakes, NJ). To detect macrophages, a rat anti-CD68 monoclonal antibody (1:100
dilution, ED1, Serotec, Oxford, UK) and rat anti-F4/80 monoclonal antibody
(1:100 dilution, A3-1, Serotec, Oxford, UK) were used. To identify MDSCs, a rat
anti-Gr-1 monoclonal antibody (1:50 dilution, RB6–8C5, BD Pharmingen,
Franklin Lakes, NJ) was used. To detect T cells and B cells, a rat anti-CD3
monoclonal antibody (1:150 dilution, 17A2, BD Pharmingen, Franklin Lakes, NJ)
and a rat anti-CD19 monoclonal antibody (1:150 dilution, 1D3, BD Pharmingen,
Franklin Lakes, NJ) were used, respectively. To detect fibroblasts, a goat anti-aSMA
polyclonal antibody (1:150 dilution, Abcam, Cambridge, MA) was used. To
determine the expression of FGF2 in the above-mentioned cells, a rabbit anti-FGF2
polyclonal antibody (1:100 dilution, Santa Cruz, Dallas, TX) or goat anti-FGF2
polyclonal antibody (1:50 dilution, Sigma, St Louis, MO) were used. A rat anti-
CD31/PECAM-1 monoclonal antibody (1:150 dilution, MEC 13.3, BD Pharmin-
gen, Franklin Lakes, NJ) and rabbit anti-NG2 polyclonal antibody (1:150 dilution,
Millipore, Billerica, MA) were used, respectively, to detect endothelial cells and
pericytes. To detect GFP-positive cells, we used a rabbit anti-GFP monoclonal
antibody (1:75 dilution, D5.1, Cell Signaling Technology, Danvers, MA) or goat
anti-GFP polyclonal antibody (1:50 dilution, Santa Cruz, Dallas, TX). To detect cell
proliferation, rabbit anti-mouse Ki67 antibody (1:150 dilution, D3B5, Cell Sig-
naling Technology, Danvers, MA) was used. Alexa488, 594 and 647-labelled sec-
ondary antibodies (1:250 dilution, Invitrogen, Carlsbad, CA) were used for
immunofluorescent detection. Nuclei were counterstained with DAPI (blue). In
each slide, the number of positive cells was counted under a fluorescent microscope
at a  200 magnification. The pericyte coverage of the tumour vasculature was
determined by performing double staining for CD31 and NG-2. The expression
levels of FGF2 in the cells in the tumour microenvironment were determined by
performing double staining for FGF2 and markers of tumour microenvironment
cells, such as collagen type I, CXCR4, CD45, CD68, F4/80, Gr-1, CD3, CD19 or
aSMA, and double positive cells were evaluated at a  400 magnification. The
expression of FGF2 in fibrocyte-like cells was determined by performing triple
staining for FGF2, collagen type I and CXCR4 at a  800 magnification. In the
GFP bone marrow chimeric mouse model, the percentages of the GFP-positive
areas were analysed using the Image J software program (National Institutes of
Health, Bethesda, MD) at a  200 magnification. To determine the bone marrow-
derived fibrocyte-like cells, triple staining of collagen type I, CXCR4 and GFP was
performed at a  800. The expression levels of FGF2 or cell proliferation in
BMDCs were determined by performing double staining for FGF2 or Ki67 and
GFP at a  400. These images were acquired by an Olympus BX61 fluorescence
light microscope (Olympus, Tokyo, Japan). The antibodies used in this study are
listed in Supplementary Table 1.
Immunohistochemical studies of mouse tumour tissue. Frozen tissue sections
(8mm thick) of tumours were fixed with 4% paraformaldehyde solution in PBS. To
detect endothelial cells, rat anti-CD31/PECAM-1 monoclonal antibody (1:100 dilution,
MEC 13.3, BD Pharmingen, Franklin Lakes, NJ) was used. To determine the hypoxia
of tumour tissue, rabbit anti-CA9 polyclonal antibody (1:1,000 dilution, Novus
Biologicals, Littleton, CO) was used. Appropriate secondary antibodies conjugated
with peroxidase (ready to use, Nichirei, Tokyo, Japan) and the 3,30-diaminobenzidine
tetrahydrochloride (DAB) Liquid System (DAKO, Carpinteria, CA) were used to
detect the immunostaining. Nuclei were counterstained with hematoxylin (DAKO).
MVD (the number of CD31þ structures per HPF) was evaluated at a  200 mag-
nification15,53,66. The CA9-positive areas were calculated using the Image J software
program (National Institutes of Health, Bethesda, MD) at a  200 magnification.
Images were acquired by Keyence BZ-9000 microscopy (Keyence, Tokyo, Japan).
Flow cytometry. The tumour tissues collected from Y-MESO-14 tumour-bearing
SCID mice were suspended to provide single cells on day 28 after tumour cell-
inoculation. To identify fibrocyte-like cells, PE-Cy7 conjugated antibodies to CD45
(1:50, 30-F11, eBioscience, San Diego, CA), Fluorescein conjugated anti-CXCR4
(1:10 dilution, 247506, R&D systems, Minneapolis, MN), and Biotin conjugated
anti-COL1A1 (1:100 dilution, Rockland, Limerick, PA) were used. To detect Biotin
conjugated antibody, PE-Streptavidin (1:1000 dilution, BD Pharmingen, Franklin
Lakes, NJ) was used. FITC conjugated anti-CD45 (1:50 dilution, 30-F11, BD
Pharmingen, Franklin Lakes, NJ) and PE conjugated antibodies to F4/80 (1:10
dilution, BM8, Biolegend, San Diego, CA) or Gr-1 (1:10 dilution, RB6–8C5, BD
Pharmingen, Franklin Lakes, NJ) were used to detect macrophages or MDSCs,
respectively. To determine the effect of AMD3100 on HSCs in bone marrow, the
bone marrow cells were harvested from the tibias and femurs of tumour (Y-MESO-
14)-bearing SCID mice on day 42 after the inoculation of tumour cells. The mice
were treated once daily with AMD3100 (5mg kg 1 per mouse) or vehicle control
by subcutaneous injection from days 7–42, in addition to bevacizumab treatment.
To identify HSCs, PE conjugated antibody to Sca-1 (1:10 dilution, D7, BD Phar-
mingen, Franklin Lakes, NJ) was used. The stained cells were analysed by flow
cytometry using a BD LSRFortessa (BD Bioscience, San Diego, CA) for acquisition
and FlowJo software (Treestar Inc, Ashland, OR) for analysis.
Patient samples. Paraffin-embedded sections from 26 lung adenocarcinoma
patients (surgery alone: n¼ 11, chemotherapy without bevacizumab: n¼ 5, che-
motherapy with bevacizumab: n¼ 10) were provided by The University of
Tokushima (Tokushima, Japan), Fukui-ken Saiseikai Hospital (Fukui, Japan),
Municipal Tsuruga Hospital (Fukui, Japan) and Kagawa University (Kagawa,
Japan). Informed consent was obtained from all patients, and the protocol was
approved by the Institutional Review Board (IRB) of Tokushima University
Hospital (No. 1750) and then by the IRB of each of the participating institutions.
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Immunohistochemical studies of the patient samples. To detect fibrocyte-like
cells in the clinical specimens, the paraffin-embedded tissues (4mm thick) were
stained with a rabbit anti-FSP-1 polyclonal antibody (1:100 dilution, Neomarkers/
Lab Vision Corporation, Fremont, CA) and mouse anti-CD45 monoclonal antibody
(1:50 dilution, 136-4B5, Cell Signaling Technology, Danvers, MA). To detect the
FGF2-positive cells, a goat anti-FGF2 polyclonal antibody (1:50 dilution, Sigma,
St Louis, MO) was used. We used a goat anti-IL-17 polyclonal antibody to detect
Th17 cells (1:50 dilution, R&D systems, Minneapolis, MN). A mouse anti-CD68
monoclonal antibody (ready to use, PG-M1, Nichirei, Tokyo, Japan) was used to
detect macrophages. A mouse anti-CD3 monoclonal antibody (1:50 dilution, F7.2.38,
Dako, Carpinteria, CA) was used to detect T-cells. To detect the B cells, mouse anti-
CD19 monoclonal antibody (1:50 dilution, LE-CD19, Dako, Carpinteria, CA) was
used. These sections were re-incubated with appropriate secondary antibodies
conjugated with peroxidase or alkaline phosphatase (ready to use, Nichirei, Tokyo,
Japan). Immunoreactivity was detected by using the DAB Liquid System or new
fuchsin (Nichirei, Tokyo, Japan), and samples were counterstained with hematox-
ylin. The number of positive cells was counted at a  400 magnification. The
expression levels of FGF2 in fibrocyte-like cells or macrophages were determined by
performing double staining for FGF2 and FSP-1 or CD68, respectively, at a  400 or
 800 magnification. Images were acquired by Keyence BZ-9000 microscopy
(Keyence, Tokyo, Japan). To detect endothelial cells, CD31 immunohistochemistry
was performed using Leica Bond-Max (Leica, Bannockburn, IL) and Bond Polymer
Refine Detection (Leica, Bannockburn, IL) according to the manufacturer’s proto-
cols. A mouse anti-human CD31 monoclonal antibody (1:50 dilution, JC70A, Dako,
Carpinteria, CA) was used as the primary antibody. To determine the microvessel
length in tumour tissue, the major axis of vessels was measured by using the BZ-9000
analytical software program (Keyence, Tokyo, Japan).
qRT-PCR. Total RNA was extracted from the tumours using an RNeasy Mini Kit
(Qiagen, Valencia, CA), and was reverse-transcribed to cDNA using a High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA)
according to the manufacturer’s instructions. RT-PCR was performed using the
CFX96 real-time PCR system (Bio-Rad, Hercules, CA) or the SYBR Premix Ex Taq
(TAKARA, Kyoto, Japan). Human RPL27 and mouse RPS29 mRNA were used as
housekeeping genes, and quantification was performed using the DD Ct method.
The specific PCR primer pairs used for each studied gene are shown in
Supplementary Table 2.
Detection of protein expression in mouse tumour tissue. Y-MESO-14 tumour
tissues were homogenized in T-PER (Pierce, Rockford, IL) containing phosphatase
and protease inhibitor cocktails (Roche, Basel, Switzerland). The concentrations of
proteins were determined using a Bio-Rad Protein Assay Kit (Bio-Rad, Richmond,
CA). Samples of 500 mgml 1 of total proteins and pleural effusion from tumour-
bearing mice were used to detect the concentrations of human VEGF, mouse
VEGF, FGF1 and FGF2 by using ELISA kits (R&D Systems, Minneapolis, MN)
according to the manufacturer’s instructions.
Induction of chemical hypoxia in vitro. Y-MESO-14 tumour cells were plated
in 24-well plates with 10% FBS containing DMEM and were incubated for 24 h.
After the incubation, 100 mM of a hypoxia-mimetic, DFX mesylate (DFX, Sigma,
St Louis, MO), was added to each well, and the cells were incubated for another
24 h to mimic the hypoxic condition. Total RNA was extracted from the hypoxic
tumour cells and the gene expression levels were compared with those in tumour
cells incubated under normoxic conditions.
Isolation of human fibrocyte-like cells. Human fibrocyte-like cells were isolated
according to previously published methods67. Mononuclear cells were isolated
from the peripheral blood of healthy volunteers using Ficoll density
centrifugation68. The isolated cells were cultured in DMEM supplemented with
20% FBS, penicillin and streptomycin on bovine fibronectin (R&D systems,
Minneapolis, MN)-coated 150mm cell culture dishes (BD Pharmingen, Franklin
Lakes, NJ). The medium was changed twice a week. After 7–10 days, the media was
aspirated and washed with sterile PBS three times. The adherent cells were
determined to be circulating fibrocyte-like cells by a flow cytometric analysis and
immunostaining67. Informed consent was obtained from all volunteers, and the
protocol was approved by the IRB of Tokushima University Hospital (No. 1586).
Purification of fibrocyte-like cells from mouse lung. Murine fibrocyte-like cells
were isolated according to previously published methods69. Murine lungs removed
from male SCID mice were minced with scissors and incubated with DMEM
including 1mgml 1 BSA (Sigma, St Louis, MO), 1mgml 1 collagenase IV
(Roche, Basel, Switzerland) and 100 mgml 1 DNase 1 (Sigma, St Louis, MO) for
1 h at 37 C. The single cell suspensions from whole lungs were incubated in
DMEM supplemented with 20% FBS in 100mm fibronectin-coated dishes. When
cells reached 70% confluence, they were passaged using trypsin digestion. After 7
days, the trypsinized cells were incubated with anti-CD45 Abs coupled to magnetic
beads (Miltenyi Biotech, Auburn, CA) for 15min on ice. The labelled cells were
separated into CD45þ (fibrocyte-like cells) and CD45 (fibroblasts) populations
using an Auto MACS instrument (Miltenyi Biotech, Auburn, CA) according to the
manufacturer’s instructions.
Purification of tumour-infiltrated fibrocyte-like cells. The tumour tissues col-
lected from Y-MESO-14 orthotopic tumour-bearing SCID mice were minced and
suspended to provide single cells on day 28 after inoculation in the same way
described above. The number of whole cells was counted using a hemocytometer,
and 3 106 suspended cells were labelled with anti-mouse CD45 magnetic beads,
and the CD45þ cells were isolated using an Auto MACS instrument. Mouse
CD45þ cells were plated in fibronectin-coated 100mm-diameter dishes and
incubated for seven days. The adherent cells were considered to be tumour-asso-
ciated fibrocyte-like cells. The number of the cells was counted using a hemocyt-
ometer, and the total RNA was extracted.
Cell migration assay for fibrocyte-like cells. Y-MESO-14 tumour cells were
plated in 24-well plates (5 104 cells per 500 ml per well) with 10% FBS containing
DMEM and were incubated for 24 h. After the incubation, the medium was
changed to 0.1% FBS containing DMEM with or without 100mM DFX, and cells
were incubated for another 24 h. The migration assay was performed using 8 mm
pore size cell culture inserts (BD Biosciences, San Jose, CA). Purified human
fibrocyte-like cells were plated in fibronectin-coated 100mm-diameter dishes, and
were incubated with DMEM supplemented with 10% FBS for 24 h. Then, the
medium was changed to 0.1% FBS containing DMEM in the presence or absence of
5 mgml 1 of the CXCR4 antagonist, AMD3100, and the cells were incubated for
1 h. After this incubation, the fibrocyte-like cells (3 105 cells per 100 ml per well)
were added to the inside of the cell culture inserts, and the inserts were put on the
Y-MESO-14 tumour cells cultured under the conditions described above. After a
3 h incubation, the cells that had migrated to the bottom surface of the filter were
stained using Diff-Quik reagents I and II (Baxter, Morton Grove, IL) and were
counted in six randomly selected fields on each filter under a microscope at a
 200 magnification.
Cell proliferation assay of HUVECs. Secondary cultures of human fibrocyte-like
cells were plated into 24-well fibronectin-coated plates (1 105 cells per well) with
the culture medium described above. After 24 h, the medium was changed to 400 ml
of 0.1% FBS containing DMEM, and the cells were incubated for an additional 48 h.
The conditioned medium was collected and stored at  80 C for further
experiments. The proliferation of HUVECs was measured using the MTT (3-[4,
5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium) dye reduction method.
HUVECs (2 103 cells per 100 ml) were plated into each well of 96-well type 1
collagen coated-plates (Iwaki, Tokyo, Japan) in 0.1% FBS containing DMEM and
were incubated for 24 h, then 100ml of the culture supernatant from fibrocyte-like
cells was added. Recombinant human VEGF protein (10 ngml 1, R&D systems,
Minneapolis, MN) or FGF protein (10 ngml 1, PeproTech, Rocky Hill, NJ) -
containing medium was added as a positive control. Then, bevacizumab (1 or
0.1 mg ml 1) or BGJ-398 (100 or 10 nM) was added, and the cells were incubated
for an additional 72 h. After the incubation, 50 ml of stock MTT solution
(2mgml 1, Sigma, St Louis, MO) was added to all of the wells, and the cells were
incubated for 2 h at 37 C. The media containing the MTT solution was removed,
and the dark blue crystals were dissolved by adding 100 ml of DMSO. The absor-
bance was measured with a SUNRISE Remote R microplate reader (Tecan, Man-
nedorf, Switzerland) at test and reference wavelengths of 550 and 630 nm,
respectively.
Microarray analysis. Total RNA was extracted from snap-frozen Y-MESO-14
tumour tissues implanted in the SCID mice with or without bevacizumab treat-
ment by using a RNeasy Mini Kit (Qiagen, Valencia, CA). The quality of the RNA
samples were confirmed using an Agilent 2100 Bioanalyzer (G2938C, Agilent
Technologies, Palo Alto, CA) employing an Agilent RNA 6000 Nano LabChip Kit
(5067-1511, Agilent Technologies, Palo Alto, CA). A total of 200 ng of total RNA
was amplified and labelled using the Agilent Low Input Quick Amp Labelling Kit,
One-Color kit (5190-2305, Agilent Technologies, Palo Alto, CA), and labelled RNA
was hybridized to Agilent Whole Human Genome Gene Expression 4 44K ver.
2.0 Micro Arrays (Agilent Technologies, Palo Alto, CA) for 17 h at 65 C. The
Agilent Feature Extraction Image Analysis Software program (Version 10.7.3,
Agilent Technologies, Palo Alto, CA) was used to extract data from the raw
microarray image files. The data visualization and analysis were performed using
the Gene Spring GX (Version 12.5, Agilent Technologies, Palo Alto, CA) software
program. Genes with an altered expression with more than 2-fold were identified
on each sample. The microarray data were deposited in the NCBI Gene Expression
Omnibus (GEO) under accession code GSE59476.
Statistical analyses. The data are presented as the means±s.e.m. The statistical
analyses were performed using Student’s t-test for unpaired samples, the Mann–
Whitney-U-test or a one-way ANOVA, followed by Tukey’s multiple-comparison
post-hoc test, were also used as appropriate. Values of Po0.05 were considered to
be statistically significant.
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